LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Contents
Segment reporting for single reportable segment
- Segment reporting for single reportable segment
The following table presents the components of net income or loss, which is the measure of profit or loss used for the Company’s single reportable segment:
| Three months ended | Six months ended | |||
|---|---|---|---|---|
| June 30,2026 | May 25,2025 | June 30,2026 | May 25,2025 | |
| Revenues | $34,167 | $36,444 | $57,360 | $71,598 |
| Personnel costs(1) | 10,952 | 12,820 | 22,469 | 25,128 |
| Materials and non-depreciation overhead(2) | 12,902 | 12,070 | 22,026 | 27,335 |
| Depreciation | 2,515 | 1,913 | 4,825 | 3,990 |
| Stock-based compensation | 2,085 | 1,815 | 3,783 | 4,367 |
| Reorganization costs | 1,247 | 2,179 | 2,789 | 4,426 |
| Loss on sale or disposal of assets | — | 91 | — | 7,727 |
| All other operating expenses(3) | 1,899 | 229 | 3,573 | 2,327 |
| Interest expense, net | 7,607 | 5,521 | 14,827 | 11,002 |
| Change in fair value of debt derivative liability | 1,203 | 1,091 | 4,358 | 1,691 |
| Other income, net | (110) | (171) | (220) | (504) |
| Income tax expense | 23 | 33 | 66 | 25 |
| Net loss | $(6,156) | $(1,147) | $(21,136) | $(15,916) |
(1)Includes all wages and salary, bonus, employer taxes, and employee benefit plan expenses
(2)Represents cost of sales, excluding direct labor and all personnel cost and depreciation allocations
(3)Includes expenses for accounting, legal and other professional services, software licensing, insurance costs, public company costs and board fees.
For the three months ended June 30, 2026, the Company earned revenue of approximately 70% in the United States,20% in Belgium and 10% in all other countries combined. For the three months ended May 25, 2025, the Company earned revenue of approximately 60% in the United States,25% in Belgium and 15% in all other countries combined. For the six months ended June 30, 2026, the Company earned revenue of approximately 75% in the United States,10% in Belgium and 15% in all other countries combined. For the six months ended May 25, 2025, the Company earned revenue of approximately 55% in the United States,30% in Belgium and 15% in all other countries combined.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.